Largest health care biotech companies by market cap
Amgen leads the 24 health care biotech companies ranked by market value, at CZK 5.34T, ahead of Gilead Sciences (CZK 4.66T) and Moderna (CZK 1.77T). Figures as of 19 Nov 2026, 08:40 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenCZK 5.34T
- Median
- CZK 236.3B
- Combined market value
- CZK 18.59T
- Countries
- 5
Market values as of .
All countries▾
Health Care▾
Biotech▾
| # | Company | Market cap ↓ | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | CZK 5.34T | CZK 9,866.25 | 3.07% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | CZK 4.66T | CZK 3,755.88 | 0.75% down | 33% up | ||
| 3 | ModernaMRNA · Health Care | CZK 1.77T | CZK 4,374.01 | 4.84% down | 755% up | ||
| 4 | argenxARGX · Health Care | CZK 1.32T | CZK 20,920.98 | 0.66% down | 4% up | ||
| 5 | BiogenBIIB · Health Care | CZK 826B | CZK 5,588.04 | 0.25% up | 49% up | ||
| 6 | Revolution MedicinesRVMD · Health Care | CZK 768.3B | CZK 3,552.29 | 1.76% down | 131% up | ||
| 7 | BioNTechBNTX · Health Care | CZK 458.8B | CZK 1,850.60 | 1.89% down | 16% down | ||
| 8 | ExelixisEXEL · Health Care | CZK 370.4B | CZK 1,517.87 | 0.31% down | 63% up | ||
| 9 | Neurocrine BiosciencesNBIX · Health Care | CZK 366.4B | CZK 3,619.86 | 1.84% down | 20% up | ||
| 10 | Bio-TechneTECH · Health Care | CZK 254B | CZK 1,617.00 | 0.17% up | 26% up | ||
| 11 | RepligenRGEN · Health Care | CZK 245.3B | CZK 3,837.90 | 6.47% up | 5% up | ||
| 12 | Halozyme TherapeuticsHALO · Health Care | CZK 242.8B | CZK 2,129.33 | 0.18% down | 37% up | ||
| 13 | Kymera TherapeuticsKYMR · Health Care | CZK 229.8B | CZK 2,692.33 | 0.32% down | 87% up | ||
| 14 | QiagenQGEN · Health Care | CZK 227.5B | CZK 1,101.56 | 0.38% down | 12% up | ||
| 15 | Krystal BiotechKRYS · Health Care | CZK 207.7B | CZK 7,009.00 | 5.62% up | 46% up | ||
| 16 | VaxcytePCVX · Health Care | CZK 205.9B | CZK 1,300.71 | 1.48% down | 22% up | ||
| 17 | Twist BioscienceTWST · Health Care | CZK 176.3B | CZK 2,586.09 | 3.88% up | 340% up | ||
| 18 | CG OncologyCGON · Health Care | CZK 158.8B | CZK 1,778.14 | 1.34% up | 85% up | ||
| 19 | ImmunityBioIBRX · Health Care | CZK 158.4B | CZK 148.92 | 7.03% up | 193% up | ||
| 20 | ImmunovantIMVT · Health Care | CZK 152.6B | CZK 737.26 | 0.12% down | 43% up | ||
| 21 | Kodiak SciencesKOD · Health Care | CZK 142.2B | CZK 2,174.00 | 1.04% up | 396% up | ||
| 22 | Scholar Rock HoldingSRRK · Health Care | CZK 130.2B | CZK 1,066.89 | 6.48% up | 14% up | ||
| 23 | Adaptive BiotechnologiesADPT · Health Care | CZK 102.4B | CZK 632.57 | 0.11% down | 88% up | ||
| 24 | CRISPR TherapeuticsCRSP · Health Care | CZK 86.7B | CZK 893.30 | 0.10% up | 21% down |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 22.2268 CZK).
Questions and answers
Which health care biotech companies rank first by market value?
Amgen (CZK 5.34T), Gilead Sciences (CZK 4.66T) and Moderna (CZK 1.77T) are the top three of the 24 health care biotech companies ranked by market value as of 19 Nov 2026, 08:40 UTC.
How many health care biotech companies are in this ranking?
24 are ranked by market value.
What are these health care biotech companies worth together?
The 24 health care biotech companies ranked by market value have a combined market value of CZK 18.59T as of 19 Nov 2026, 08:40 UTC.
What does ranking by market value measure?
What the stock market values the whole company at: its share price times the number of its shares.
Learn how this ranking works
All markets guides →- What market capitalization is, and what it is not
Market capitalization is the share price multiplied by the number of shares outstanding: 1 billion shares at $50 is a $50 billion company. It measures the size the stock market puts on a company's equity today. It is not a sale price, it ignores debt and cash, and index providers often count only the freely traded part, the float.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest health care biotech companies by market cap”, data as of 19 November 2026. https://funkfolio.com/companies/category/biotech?sector=health-care
Underlying data: Yahoo Finance; SEC EDGAR.